SANTYL ®. We are confident that EscharEx will provide meaningful benefits to patients, healthcare providers, and payors alike.” The VALUE study is a global, multicenter, prospective ...
EscharEx has already demonstrated its ability to effectively and rapidly debride chronic wounds in multiple Phase II trials, surpassing the current $375+ million market leader in wound debridement, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback